AR005551A1 - Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple - Google Patents

Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple

Info

Publication number
AR005551A1
AR005551A1 ARP970100303A ARP970100303A AR005551A1 AR 005551 A1 AR005551 A1 AR 005551A1 AR P970100303 A ARP970100303 A AR P970100303A AR P970100303 A ARP970100303 A AR P970100303A AR 005551 A1 AR005551 A1 AR 005551A1
Authority
AR
Argentina
Prior art keywords
immunosuppressants
treatment
combination
infections
cytotoxic agent
Prior art date
Application number
ARP970100303A
Other languages
English (en)
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10787583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR005551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of AR005551A1 publication Critical patent/AR005551A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La composición farmacéutica comprende un nucleósido análogo activo frente al virus herpes simple, talcomo aciclovir/valaciclovir o penciclovir/famciclovir, y un inmunosupresor, como preparación combinada para el uso simultáneo, por separadoo secuencial en el tratamiento y/o prevención deinfecciones por el virus del herpes simple. También se propone el uso de análogs en combinación con inmunosupresores en la fabricación de lascomposiciones mencionadas.
ARP970100303A 1996-01-26 1997-01-24 Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple AR005551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9601544.1A GB9601544D0 (en) 1996-01-26 1996-01-26 Pharmaceuticals

Publications (1)

Publication Number Publication Date
AR005551A1 true AR005551A1 (es) 1999-06-23

Family

ID=10787583

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100303A AR005551A1 (es) 1996-01-26 1997-01-24 Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple

Country Status (26)

Country Link
US (5) US6514980B1 (es)
EP (1) EP0876146B1 (es)
JP (1) JP2000507211A (es)
KR (1) KR19990081966A (es)
CN (1) CN1133433C (es)
AR (1) AR005551A1 (es)
AT (1) ATE238796T1 (es)
AU (1) AU713202B2 (es)
BR (1) BR9707304A (es)
CY (1) CY2421B1 (es)
CZ (1) CZ297841B6 (es)
DE (1) DE69721484T2 (es)
DK (1) DK0876146T3 (es)
ES (1) ES2199339T3 (es)
GB (1) GB9601544D0 (es)
HK (1) HK1016475A1 (es)
HU (1) HU226793B1 (es)
IL (1) IL125075A (es)
NO (1) NO316355B1 (es)
NZ (1) NZ326839A (es)
PL (1) PL187076B1 (es)
PT (1) PT876146E (es)
TR (1) TR199801439T2 (es)
TW (1) TW493985B (es)
WO (1) WO1997026882A1 (es)
ZA (1) ZA97608B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438585B (en) 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
US7591945B2 (en) * 2003-02-07 2009-09-22 Gambro Lundia Ab Support device for containers in extracorporeal blood treatment machines
CN104997783A (zh) * 2005-03-25 2015-10-28 Alt解决方案公司 端粒酶阳性细胞中端粒长度的调节和癌症治疗
CN101588805A (zh) * 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
WO2011035120A2 (en) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Therapeutic composition to treat lesions caused by herpes simplex virus
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) * 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US3322627A (en) * 1964-09-03 1967-05-30 Merck & Co Inc Method of treating herpes simplex infections with 5-methylamino-2'-deoxyuridine, and compositions therefor
GB9001886D0 (en) * 1990-01-26 1990-03-28 Beecham Group Plc Pharmaceutical formulation
GB9015051D0 (en) * 1990-07-07 1990-08-29 Beecham Group Plc Pharmaceutical treatment
DE69306545T2 (de) 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
GB9426021D0 (en) 1994-12-22 1995-02-22 Smithkline Beecham Plc Pharmaceuticals
TW438585B (en) * 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
CN1209748A (zh) 1999-03-03
NZ326839A (en) 2001-02-23
ZA97608B (en) 1998-07-24
PL187076B1 (pl) 2004-05-31
DE69721484T2 (de) 2004-02-26
CZ297841B6 (cs) 2007-04-11
CY2421B1 (en) 2004-11-12
WO1997026882A1 (en) 1997-07-31
BR9707304A (pt) 1999-07-20
US6514980B1 (en) 2003-02-04
IL125075A (en) 2003-02-12
IL125075A0 (en) 1999-01-26
US20040185433A1 (en) 2004-09-23
PT876146E (pt) 2003-09-30
US20100323952A1 (en) 2010-12-23
ES2199339T3 (es) 2004-02-16
ATE238796T1 (de) 2003-05-15
EP0876146B1 (en) 2003-05-02
HU226793B1 (en) 2009-10-28
HK1016475A1 (en) 1999-11-05
US20080287389A1 (en) 2008-11-20
NO316355B1 (no) 2004-01-19
NO983402D0 (no) 1998-07-23
CZ234098A3 (cs) 1999-02-17
US20050222016A1 (en) 2005-10-06
PL327917A1 (en) 1999-01-04
EP0876146A1 (en) 1998-11-11
HUP9900945A2 (hu) 1999-07-28
JP2000507211A (ja) 2000-06-13
TW493985B (en) 2002-07-11
DE69721484D1 (de) 2003-06-05
KR19990081966A (ko) 1999-11-15
CN1133433C (zh) 2004-01-07
AU1550697A (en) 1997-08-20
AU713202B2 (en) 1999-11-25
TR199801439T2 (xx) 1998-10-21
NO983402L (no) 1998-07-23
GB9601544D0 (en) 1996-03-27
DK0876146T3 (da) 2003-08-11
HUP9900945A3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
MY109796A (en) 1,3-oxathiolane nucleoside analogues.
MX9200361A (es) Nuevo uso del antagonista de adenosina.
EP0375329A3 (en) Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
IL152925A (en) Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
WO1993017020A3 (en) Therapeutic nucleosides
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
BR0010181A (pt) Composição farmacêutica de dosagem unitária e seu uso
AR005551A1 (es) Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
KR870006900A (ko) 항바이러스 조성물
WO2000053167A3 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
BR9910071A (pt) Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
AR023661A1 (es) Combinaciones antivirales
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
CA2244268A1 (en) Nucleoside analogs in combination therapy of herpes simplex infections
CA2429114A1 (en) Treatment of premature ejaculation
AR023705A1 (es) COMPOSICIoN ToPICA QUE COMPRENDE EL GLUCOCORTICOIDE ANTIINFLAMATORIO HIDROCORTISONA Y UN AGENTE ANTIVIRAL ANALOGO DE NUCLEOSIDO ACICLOVIR Y EL USO DE LA MISMA
CO4790095A1 (es) Derivados de tienoxacinona inhibodores de la proteasa del herpes
DK0650363T3 (da) Antivirale kombinationer
KR920019362A (ko) 디데옥시 아데노신 및 아데노신 데아미나제 억제물질을 포함하는, 항-hiv활성을 지닌 치료학적 조성물
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
GEP19970908B (en) Esters of 9-(2-hydroxyethoxymethyl)guanine having antiviral properties

Legal Events

Date Code Title Description
FC Refusal